One-gene safety check before capecitabine or 5-FU chemotherapy starts
TL;DR Enzymark is a lab test for one gene, DPYD, that tells an oncologist whether a patient may break down 5-FU or capecitabine too slowly and suffer severe toxicity. Results arrive before the first cycle. Oncology day-care centres order it and patients pay a modest fee. It works because the drugs are common and testing in India is rare.
Fluoropyrimidines (5-FU and capecitabine) are backbone drugs for bowel, stomach, breast and other cancers. People with low activity of the DPD enzyme clear them slowly and can get severe diarrhoea, mouth ulcers or blood-count crashes. At Tata Memorial, 31 of 506 capecitabine patients had grade 3 or 4 toxicity in their first cycle, and most of those tested carried DPYD variants[1]. An AIIMS study published in February 2026 states plainly that routine DPYD genotyping is not common practice in India[2]. So most patients find out the hard way, in the first cycle.
What it does, in regulatory terms: a laboratory test that informs dosing. Enzymark reports a genotype and the matching guideline category, and the oncologist decides the dose. It makes no claim to prevent toxicity on its own.
The oncology centre draws a blood sample when chemotherapy is planned. A courier takes it to an accredited partner lab, which runs a targeted DPYD assay and returns a one-page report within two to three working days, timed to the first cycle. The report states whether the patient is a normal, intermediate or poor metaboliser and which European or international guidance applies. A short helpline lets oncologists ask a pharmacist or geneticist about borderline results.
The seed proposed a broad pharmacogenomic insights platform, and I narrowed it. Broad panels already exist and rarely change what gets prescribed, but a single gene tied to one dated decision is far easier to sell and to prove useful.
The patient benefits, the oncologist orders, and the patient usually pays out of pocket alongside chemotherapy costs. Hospital chains and day-care networks are the buyer to win, because they can make the test part of their standard chemo pathway. I found no public Indian price for a stand-alone DPYD test, so check local lab menus before you set yours.
Europe's medicines regulator told doctors in April 2020 to test for DPD deficiency before giving these drugs[3]. Indian evidence is catching up - the 2016 Tata Memorial series and the 2026 AIIMS sequencing study both argue for more testing[1][2]. Cancer volumes keep rising, with an estimated 15.6 lakh new cases in 2024[4].
There is no public count of Indian patients starting fluoropyrimidines each year. Adjacent: 15.6 lakh new cancer cases in 2024[4], with gastrointestinal and breast cancers among the common users of these drugs. Prevalence data conflict. The AIIMS study found 3.9% intermediate metabolisers in 76 unselected patients[2], while the Tata Memorial series looked only at patients already harmed[1]. Read both before sizing anything.
One large genomics lab sells pharmacogenomic panels for antiepileptic and thiopurine drugs, but lists no DPYD product on its home page[5]. A consumer DNA brand sells a drug-response report[6]. Hospital labs at a few large centres run DPYD tests in research settings. The gap is a fast, single-purpose test that day-care centres can order as routinely as a blood count.
| Difficulty | Moderate (47/100) |
| Starting capital | ₹1.2–2.2 Cr |
| Time to launch | 9–12 months |
The assay itself is established. The hard parts are getting turnaround under three days across cities, earning accreditation, and changing oncologists' habits when Indian guidelines do not yet require the test. Expect a year of education talks and pilot data before volumes move.
Yes. You run a medical test on patient samples, so the lab side is regulated.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI make the genotype call or suggest a dose. A wrong output here reaches a chemotherapy decision, so a qualified person signs every report.
Want to work out the AI layer for Enzymark? Talk to Yash →
Here's what can go south -
I think this is a sensible, narrow business for a founder with diagnostics-lab experience and oncology contacts. If you want a consumer genetics brand then this is the wrong idea. First prove that two day-care chains will make the test standard before cycle one, and that doses actually change when a variant is found.
Plan for roughly ₹1.2–2.2 Cr, most of it on the partner lab setup, validation and getting oncology centres on board.
As a lab service you need NABL ISO 15189 accreditation and DPDP compliance. A CDSCO IVD licence only applies if you sell your own kit.
Yes. European regulators already recommend DPD testing before these drugs, so check your local lab accreditation and medical device rules first.
The free Enzymark validation kit has the line-by-line capital breakdown, the effort scoring, the lab accreditation and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for oncologists and centres, and 5 assumptions to test. Download the kit →
Thinking about building Enzymark or something close to it? The make-or-break work is a three-day turnaround and the first chain that makes testing routine, and I'm glad to work through both with you. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.